Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

APhA Publishes Reference On Drugs And Substances Of Abuse
The American Pharmacists Association (APhA) will publish in mid-July the second edition of Pagliaros" Comprehensive Guide to Drugs and Substances of Abuse. Written by veteran authors Louis A. Pagliaro and Ann Marie Pagliaro, the reference includes more than 100 monographs-11 of them new-dealing with each of the major drugs and substances of abuse used in North America, from acetone to zopiclone.
generic viagra online
A Feasible, Simple And Convenient Model For Study Of Rectal Carcinoma
The method of building a rabbit rectal VX2 carcinoma model by injecting the cell suspension of VX2 cells into the wall of the rectum guided by X-ray fluoroscopy is feasible. The advantages of the model are ease of establishment, short growth period, and high stability. The rectal VX2 carcinoma established in this rabbit model is similar to human rectal carcinoma in aspects of pathological representation, tumor development, and metastasis. It offers an ideal major animal model for the study of rectal carcinoma, and especially profits the study of the staging of rectal carcinoma in imaging.
News of the day
Government Of Canada Acts To Help Ensure Soft Vinyl Toys, Child-Care Articles And Other Consumer Products Are Safer
The Honourable Leona Aglukkaq, Minister of Health, announced today that the Government of Canada is proposing new regulations to prevent the use of six chemicals (phthalates) in soft vinyl toys and child-care articles. Regulations are also being proposed to further reduce lead limits in consumer products.
Mental Health

Spectranetics Receives CE Mark Approval For ThromCat(R)XT

Spectranetics Corporation (Nasdaq:SPNC) reported that it has received the CE mark approval for its next-generation ThromCat® XT Thrombus Removal System, a single-use, disposable device indicated for mechanical removal of thrombus from native coronary arteries and infra-inguinal arteries. The launch of the product will commence immediately within the European Union. The approval triggers a milestone payment of $1.5 million pursuant to the Company"s Amended Development and Regulatory Services agreement with Kensey Nash Corporation (Nasdaq:KNSY). The ThromCat XT System is an improvement to the current ThromCat System with enhanced thrombus removal and several advancements in ease-of-use. The ThromCat XT System generates a consistent vacuum pressure at the tip of the catheter to draw thrombus into the extraction ports where it is then macerated by an internal helix. Without further contact with the blood stream, the thrombus is then transported to an external collection bag. The ThromCat XT is completely disposable and offered in 150cm length to treat vessels 2.5 - 7 mm in diameter. The first use of the ThromCat XT System occurred in a procedure performed by Dr. Danny Nguyen in consultation with Prof. dr. med Michael Haude of the Department of Cardiology, Stç¤dtische Kliniken Neuss- Lukaskrankenhaus in Neuss, Germany. The intervention was performed on a 70-year-old female patient with heart failure and a totally occluded Right Coronary Artery (RCA). Thrombectomy was successfully completed with the ThromCat XT, and was followed by direct stenting of the proximal and middle sections of the RCA, restoring normal flow. Prof. Haude and Dr. Nguyen commented after the procedure, "We are very satisfied with the overall performance of the ThromCat XT. In contrast to the previous version of the ThromCat, the set up time was significantly shortened, and the device was easy to use. In addition, this new version of the ThromCat provides better pushability and trackability within the vessel. The device was able to remove virtually all thrombus from a 100% occluded vessel that contained significant thrombus burden. We are very happy with the result for the patient after doing the first ThromCat XT case." "European thrombectomy revenue currently represents nearly half of Spectranetics" worldwide thrombectomy sales and is a key growth driver of international revenue. I am pleased that we will be able to launch the newly designed ThromCat XT System in this important market and are currently in discussions with the Food and Drug Administration to identify the regulatory pathway for the ThromCat XT system in the United States," said Emile J. Geisenheimer, Chairman, President and Chief Executive Officer. Spectranetics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009